Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: Dapagliflozin: Tab. Dapagliflozin (10 mg) once daily
Intervention2: Dapagliflozin: Tab. Dapagliflozin (10mg) oncedaily for 3months.
Control Intervention1: Empagliflozin: Tab. Empagliflo
Sponsors
All India Institute Of Medical Sciences, Patna
Eligibility
Inclusion criteria
Inclusion criteria: 1.Previously diagnosed type 2 Diabetes Mellitus patient already on Metformin (1000mg/day) >=3 month with FBS >=130 mg/dl or PPBS >=180mg/dl or HbA1C >=7% 2. Age: >=18years and 3. Gender: Both
Exclusion criteria
Exclusion criteria: 1.Patient already on diabetic treatment on drugs other than Metformin. 2.Patient with Renal disease (S. Creatinine >=1.2mg/dl) Liver disease (ALT/AST >50IU) 3.Pregnant and lactating women 4.Patients unwilling/unable to give consent 5.Patient on drugs which may cause hyperglycaemia like (Steroids, Beta2 agonist, Thiazides, Antipsychotics) . 6.Patient on drugs causing hypoglycaemia (Beta blocker, Fluoroquinolones, Pentamidine). 7. Patient on drugs causing derangement of vitamin D, PTH level (Phenytoin, phenobarbital, warfarin, Cyclophosphamide, Tamoxifen, Rifampicin, Antiviral drugs). 8. Patient on vitamin D medication and calcium medication. 9. Patient on drugs which derange calcium metabolism (Thiazides, Loop diuretics). 10. Patient with vitamin D level less than 20 ng/ml.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of Empagliflozin versus Dapagliflozin on circulating markers of calcium-phosphate metabolismTimepoint: 0 month, 3 month | — |
Secondary
| Measure | Time frame |
|---|---|
| i) Efficacy of Empagliflozin versus Dapagliflozin on blood glucose parameters. ii) Adverse drug reaction profile (ADR Profile) in patients receiving Empagliflozin versus Dapagliflozin. Timepoint: 0 month, 1 month, 2 month, 3 month | — |
Countries
India
Contacts
Public ContactDr Shuvasree Payra
AIIMS,PATNA
Outcome results
None listed